차바이오텍은 줄기세포, 면역세포와 관련된 다양한 원천 기술을 활용해 세포치료제를 개발하고 있습니다. 세포치료제에 국한하지 않고 유전자까지 포함한 Cell(세포) &Gene(유전자) 분야로 연구개발을 확장, 범용 치료제 개발과 재생의료, CDMO 등 더 넓은 분야로 진출하고 있습니다.
ChaBiotech raises 10 billion won through private placement
ChaBiotech announced a private placement to raise 10 billion won for operating funds. The company will issue 771,664 new shares at 12,959 won each to LG CNS.
Cha Vaccine Institute faces financial pressure due to convertible bond redemption. Parent company Cha Biotech's support capacity is limited. Shingles vaccine pipeline crucial for improving profitability.
JPMorgan: Crypto Market Structure Act likely to pass mid-year
JPMorgan predicts the Crypto Market Structure Act will likely pass by mid-2026, potentially transforming the crypto market and attracting institutional investors.